GSK3B and non-small cell lung carcinoma: Other researchers also demonstrated that diosmetin can interact synergistically with anticancer drugs in other cancer cells, for example, diosmetin combined with paclitaxel synergistically induced apoptosis in non-small cell lung cancer cells via Nrf2 inhibition through disruption of PI3K/Akt/GSK-3β pathway [20].